Analysis

Discovered in 2015, MOTS-c is encoded within the mitochondrial 12S rRNA gene. Lee 2015 (Cell Metabolism) is the foundational mechanism paper; the peptide acts on AMPK and folate-cycle pathways. The human translational dossier is thin, small-cohort pilot data on glucose tolerance and insulin sensitivity. Methodology v1.2 places it firmly in the research-peptide tier.

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. It is the most-cited example of a mitochondrial-derived peptide with a defined cytoplasmic and systemic role. Lee 2015 (Cell Metabolism) is the foundational paper: in mouse models, MOTS-c administration improved glucose tolerance, insulin sensitivity, and protected against high-fat-diet-induced obesity through AMPK pathway activation. Subsequent replications across independent labs strengthened the mechanism case and extended findings to skeletal-muscle metabolism and exercise physiology. The human data layer remains thin. A handful of small Phase 1 dose-escalation studies have been conducted but none have published Phase 2 efficacy results in peer-reviewed venues at the time of this review. Methodology v1.2 scores MOTS-c 5.9. The mechanism is strong, the human evidence is weak. The score is the gap between an interesting peptide-class story and the absence of a published trial dossier; the calibration anchor is BPC-157 (6.8) which has more preclinical depth and one published human pilot. Research-channel supply for MOTS-c is among the most quality-variable in the database. Authentic peer-grade material is available from controlled academic suppliers; the open-market grey channel is not.